Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
Children's Mercy Hospital Kansas City
Summary
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
Eligibility
- Age range
- 1–17 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Received a heart transplant * At least 1 year after transplant * At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab) * At least 1 year from anti-thymocyte globulin * At least 6 months after pulse dose steroid treatment or basiliximab treatment * No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion * Clinically well Exclusion Criteria: * History of repeated infections necessitating adjustment in imm…
Interventions
- DrugCommercial measles, mumps, and rubella (MMR) vaccine
Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.
Location
- Children's Mercy HospitalKansas City, Missouri